Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 46.88
- Piotroski Score 2.00
- Grade Buy
- Symbol (WRN)
- Company Western Copper and Gold Corporation
- Price $1.17
- Changes Percentage (-9.27%)
- Change -$0.12
- Day Low $1.17
- Day High $1.31
- Year High $1.66
Western Copper and Gold Corporation, an exploration stage company, engages in the exploration and development of mineral properties in Canada. The company explores for gold, copper, silver, and molybdenum deposits. Its principal property is the Casino mineral property that comprise 1,136 full and partial quartz claims, and 55 placer claims located in Yukon, Canada. The company was formerly known as Western Copper Corporation and changed its name to Western Copper and Gold Corporation in October 2011. Western Copper and Gold Corporation was incorporated in 2006 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $4.25
- High Stock Price Target $4.25
- Low Stock Price Target $4.25
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.01
- Trailing P/E Ratio -118
- Forward P/E Ratio -118
- P/E Growth -118
- Net Income $-3,338,299
Income Statement
Quarterly
Annual
Latest News of WRN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Investing in Newron Pharmaceuticals (VTX:NWRN) three years ago would have delivered you a 294% gain
Newron Pharmaceuticals' stock price has surged 294% in three years, with revenue growing at 16% annually. While the company isn't profitable yet, the market shows optimism. Shareholders received a 28%...
By Yahoo! Finance | 1 month ago -
We Might See A Profit From Newron Pharmaceuticals S.p.A. (VTX:NWRN) Soon
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focusing on CNS and pain treatments. Analysts predict the company will break even in 2024, with a projected 51% annual growth rate. Despite...
By Yahoo! Finance | 2 months ago
